The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program
Keywords:
Tay-Sachs disease, Genetic screening, HEXA gene, Jewish population, Molecular diagnosisAbstract
CONTEXT: Tay-Sachs disease is an autosomal recessive disease characterized by progressive neurologic degeneration, fatal in early childhood. In the Ashkenazi Jewish population the disease incidence is about 1 in every 3,500 newborns and the carrier frequency is 1 in every 29 individuals. Carrier screening programs for Tay-Sachs disease have reduced disease incidence by 90% in high-risk populations in several countries. The Brazilian Jewish population is estimated at 90,000 individuals. Currently, there is no screening program for Tay-Sachs disease in this population. OBJECTIVE: To evaluate the importance of a Tay-Sachs disease carrier screening program in the Brazilian Jewish population by determining the frequency of heterozygotes and the acceptance of the program by the community. SETTING: Laboratory of Molecular Genetics – Institute of Biosciences – Universidade de São Paulo. PARTICIPANTS: 581 senior students from selected Jewish high schools. PROCEDURE: Molecular analysis of Tay-Sachs disease causing mutations by PCR amplification of genomic DNA, followed by restriction enzyme digestion. RESULTS: Among 581 students that attended educational classes, 404 (70%) elected to be tested for Tay-Sachs disease mutations. Of these, approximately 65% were of Ashkenazi Jewish origin. Eight carriers were detected corresponding to a carrier frequency of 1 in every 33 individuals in the Ashkenazi Jewish fraction of the sample. CONCLUSION: The frequency of Tay-Sachs disease carriers among the Ashkenazi Jewish population of Brazil is similar to that of other countries where carrier screening programs have led to a significant decrease in disease incidence. Therefore, it is justifiable to implement a Tay-Sachs disease carrier screening program for the Brazilian Jewish population.
Downloads
References
Gravel RA, Clarke JT, Kaback MM, Mahuran D, Sandhoff K, Suzuki K. The GM2 gangliosidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle DV, editors. The metabolic and molecular bases of inherited disease. 7th ed., New York: McGraw-Hill; 1995:2839-79.
Takeda K, Nakai H, Hagiwara H, et al. Fine assignment of beta- hexosaminidase A alpha-subunit on 15q23-q24 by high-resolu- tion in situ hybridization. Tohoku J Exp Med 1990;160:203-11.
Nakai H, Byers MG, Nowak NJ, Shows TB. Assignment of beta-hexosaminidase A alpha-subunit to human chromosomal region 15q23-q24. Cytogenet Cell Genet 1991;56:164.
Navon R, Proia RL. The mutations in Ashkenazi Jews with adult GM2 gangliosidosis, the adult form of Tay-Sachs disease. Sci-
ence 1989;243:1471-4.
Conzelmann E, Kytzia H-J, Navon R, Sandhoff K. Ganglioside GM2 N-acetyl-beta-D-hexosaminidase activity in cultured fibroblasts of late-infantile and adult GM2 gangliosidosis patients and of healthy probands with low hexosaminidase level. Am J Hum Genet 1983;35:900-13.
Petersen GM, Rotter JI, Cantor RM, et al. The Tay-Sachs dis- ease gene in North American Jewish populations: geographic variations and origins. Am J Hum Genet 1983; 35:1258-69.
Schneck L, Valenti C, Amsterdam D, Friedland M, Adachi M, Volk BW. Prenatal diagnosis of Tay-Sachs disease. Lancet 1970;1:582-3.
O’Brien JS, Okada S, Chen A, Fillerup DL. Tay-Sachs disease: detection of heterozygotes and homozygotes by serum hexosaminidase assay. N Engl J Med 1970;283:15-20.
O’Brien, JS, Okada S, Fillerup DL, Veath ML, Adornato BT, Brenner PH, Leroy JG. Tay-Sachs disease: prenatal diagnosis. Science 1971;172:61-4.
Kaback MM, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K. Tay-Sachs disease – carrier screening, prenatal diagnosis, and the molecular era – an international perspective, 1970 to 1993. J Am Med Assoc 1993; 270:2307-15.
Triggs-Raine B, Feingenbaum ASJ, Natowicz MR, et al. Screen- ing for carriers of Tay-Sachs disease among Ashkenazi Jews: a comparison of DNA-based and enzyme-based tests. New Eng J Med 1990;323:6-12.
Fernandes MJG, Kaplan F, Clow CL, Hechtman P, Scriver CR. Specificity and sensitivity of hexosaminidase assays and DNA analysis for the detection of Tay-Sachs disease gene carriers among Ashkenazi Jews. Genetic Epidemiology 1992; 9:169- 75.
Myerowitz R, Costigan FC. The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha- chain of beta-hexosaminidase. J Biol Chem 1988;263:18587- 9.
Arpaia E, Dumbrille-Ross A, Maler T, et al. Identification of an altered splice site in Ashkenazi Tay-Sachs disease. Nature 1988;333:85-6.
Ohno K, Suzuki K. A splicing defect due to an exon-intron junctional mutation results in abnormal beta-hexosaminidase alpha chain mRNAs in Ashkenazi Jewish patients with Tay-Sachs disease. Biochem Biophys Res Commun 1988;153:463-9.
Paw BH, Kaback MM, Neufeld EF. Molecular basis of adult- onset and chronic GM2 gangliosidoses in patients of Ashkenazi Jewish origin: substitution of serine for glycine at position 269 of the alpha-subunit of beta-hexosaminidase. Proc Nat Acad Sci 1989;86:2413-7.
Instituto Brasileiro de Geografia e Estatística. Censo demográfico do Brasil, 1991. Rio de Janeiro: IBGE; 1992.
Richards B, Skoletsky J, Shuber AP, et al. Multiplex PCR am- plification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet 1993;2:159-63.
Rattner H. Tradição e mudança: a comunidade judaica em São Paulo. São Paulo: Ática; 1977:191.
Goodman RM. A perspective on genetic diseases among the Jewish people. In: Goodman RM, Motulsky AG, editors. Ge- netic diseases among Ashkenazi Jews. New York: Raven Press; 1979:1-17.
Palomaki GE, Williams J, Haddow JE, Natowicz MR. Tay-Sachs disease in persons of French-Canadian heritage in northern New England. Am J Med Genet 1995;56:409-12.
Blitzer MG, McDowell GA. Tay-Sachs disease as a model for screening inborn errors. Clin Lab Med 1992;12:463-80.
Mitchell JJ, Capua A, Clow C, Scriver CR. Twenty-year out- come analysis of genetic screening programs for Tay-Sachs and b-Thalassemia disease carriers in high schools. Am J Hum Genet 1996;59:793-98.
Levin, M. Screening Jews and Genes: A consideration of the ethics of genetic screening within the Jewish community: chal- lenges and responses. Genetic Testing; 1999;3:207-213.
Zeesman S, Clow CL, Cartier L, Scriver CR. A private view of heterozigozity: eight-year follow-up study of the Tay-Sachs gene detected by high school screening in Montreal. Am J Med Genet 1984;18:769-78.
Buchalter MS, Wannmacher CMD, Wajner M. Tay-Sachs dis- ease: screening and prevention program in Porto Alegre. Rev Brasil Genet VI 1983;3:539-47.
Schmidt JS, Diament AJ, Krynski S, Kamei ME, Rodrigues MM, Takata S. Detección de errores congénitos del metabolismo en San Pablo, Brasil. Bol Méd Hosp Infant Méx 1981;38:217-29.
Kaplan F. Tay-Sachs disease carrier screening: a model for pre- vention of genetic disease. Genetic Testing 1998;4:271-92.
